Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)

Viking Therapeutic (VKTX) PT Raised to $36 at BTIG, 'We don’t see this SAE being of concern'

BTIG analyst Justin Zelin raised the price target on Viking Therapeutic (NASDAQ: VKTX) to $36.00 (from $31.00) while maintaining a Buy rating.

The analyst comments "

We are very impressed by this mornings very positive topline data for the highly anticipated VOYAGE Phase 2 NASH Study of VK2809 positioning VK2809 as a best-in-class THRB with a doubling of efficacy on MRI-PDFF reductions at 8-10x less of a dose and a significantly better safety profile than Madrigals (MDGL, Not Rated) resmiterom. Up to 52% mean liver fat reduction was noted in the 10mg QOD... More

Truist Securities on Viking Therapeutic (VKTX): 'Data Looks Clean On Safety/Tolerability'

Truist Securities analyst Joon Lee reiterated a Buy rating and $32.00 price target on Viking Therapeutic (NASDAQ: VKTX).

The analyst comments "VKTX reported topline data from Ph2b VOYAGE showing impressive efficacy and tolerability across doses (Exhibit 1). Moreover, we think the data looks numerically superior to Madrigal's (MDGL, NR) resmetirom on both efficacy (liver fat reduction) and tolerability... More